nnc 45-0095 nnc 45-0095 nc 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator (serm) which was under development by novo nordisk for the treatment of postmenopausal osteoporosis but was never marketed. it is a partial agonist of the estrogen receptor (ic50 (for binding inhibition) = 9.5 nm; ec50 = 13 nm) with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus (emax (relative to moxestrol, in ishikawa endometrial cancer cell line) = 105%). the compound is a pyrroloindolizine derivative. its development was discontinued by 2003. nnc 45-0095clinical dataother namesnnc-450095drug classselective estrogen receptor modulatoridentifiers iupac name 4-(1-ethylpyrroloindolizin-2-yl)phenol cas number217318-90-6pubchem cid9903336chemspider8078990uniiis4m82c29xchemblchembl420017comptox dashboard (epa)dtxsid60432621 chemical and physical dataformulac18h15nomolar mass261.324 g·mol−13d model (jsmol)interactive image smiles ccc1=c(c2=cc=c3n2c1=cc=c3)c4=cc=c(c=c4)o inchi inchi=1s/c18h15no/c1-2-15-16-5-3-4-13-8-11-17(19(13)16)18(15)12-6-9-14(20)10-7-12/h3-11,20h,2h2,1h3key:gbhfdpqplxkniu-uhfffaoysa-n